28 September 2020

Incanthera plc

("Incanthera" or the "Company")

Sol Skin Cancer Technology

Successful Results of Sensitisation Study

Incanthera plc (AQSE: INC), the specialist oncology company focused on transforming cancer treatment, is pleased to announce that it has received positive data from a skin sensitisation study of its skin cancer technology Sol.

Sol is a proprietary topical formulation designed to deliver into the skin an active known to prevent the formation of solar (actinic) keratosis and skin cancer.

The study, conducted by XCellR8 Ltd, has demonstrated that our Sol formulation was found to be "non-irritant" using ex-vivo human skin.

Formerly, studies carried out in collaboration between XCellR8 Ltd and Cutest Ltd (a CRO with particular expertise in clinical trials using topical applications) have demonstrated very good correlation between results using the methodology of this study and those obtained in clinical mildness studies.

Sol's "non-irritancy" was found to be comparable to baby sun protection products tested previously, with Sol scoring better those products which they would define as "very mild".

The Company is delighted with the results, which demonstrate that Sol is "non-irritant". The comfort and safety of human skin's reaction to the topical application of Sol is a further valuable marker of the asset and this technology.

These results add to the data announced on 22 September 2020, showing the exemplary penetration capabilities of Sol into the skin where it could deliver the required  bioequivalent level shown to be clinically effective.

Commenting on the announcement, Chairman, Tim McCarthy said:

"This additional positive data on Sol, greatly enhances the product's overall profile and supports our ongoing negotiations with potential commercial partners."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The directors of the Company take responsibility for this announcement.

For further enquiries:

Notes to Editors:

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com